6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells

详细信息    查看全文

• 作者：Brian K Flesner ; Senthil R Kumar ; Jeffrey N Bryan
• 关键词：Lymphoma ; Demethylation ; Thioguanine ; DNMT ; Canine
• 刊名：BMC Veterinary Research
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：10
• 期：1
• 全文大小：530 KB
• 参考文献：1. Marconato, L, Gelain, ME, Comazzi, S (2013) The dog as a possible animal model for human non- Hodgkin lymphoma: a review. Hematol Oncol 31: pp. 1-9 CrossRef
  2. Garrett, LD, Thamm, DH, Chun, R, Dudley, R, Vail, DM (2002) Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 16: pp. 704-709 CrossRef
  3. Alvarez, FJ, Kisseberth, WC, Gallant, SL, Couto, CG (2006) DMAC protocol for dogs with relapsed lymphoma. J Vet Intern Med 20: pp. 1178-1183 CrossRef
  4. Dervisis, NG, Dominguez, PA, Sarbu, L, Newman, RG, Cadile, CD, Swanson, CN, Kitchell, BE (2007) Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. J Am Vet Med Assoc 231: pp. 563-569 CrossRef
  5. Flory, AB, Rassnick, KM, Al-Sarraf, R, Bailey, DB, Balkman, CE, Kiselow, MA, Autio, K (2008) Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. J Vet Intern Med 22: pp. 164-171 CrossRef
  6. Rassnick, KM, Mauldin, GE, Al-Sarraf, R, Mauldin, GN, Moore, AS, Mooney, SC (2002) MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-000). J Vet Intern Med 16: pp. 576-580
  7. Saba, CF, Thamm, DH, Vail, DM (2007) Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med 22: pp. 164-171
  8. Baur, AS, Shaw, P, Burri, N, Delacretaz, F, Bosman, FT, Chaubert, P (1999) Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 94: pp. 1773-1781
  9. Li, Y, Nagai, H, Ohno, T, Yuge, M, Hatano, S, Ito, E, Mori, N, Saito, H, Kinoshita, T (2002) Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 100: pp. 2572-2577 CrossRef
  10. Rossi, D, Capello, D, Gloghini, A, Franceschetti, S, Paulli, M, Bhatia, K, Saglio, G, Vitolo, U, Pileri, SA, Esteller, M, Carbone, A, Gaidano, G (2004) Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89: pp. 154-164
  11. Mears, EA, Raskin, RE, Legendre, AM (1997) Basophilic leukemia in a dog. J Vet Intern Med 11: pp. 92-94 CrossRef
  12. Rohrig, KE (1983) Acute myelomonocytic leukemia in a dog. J Am Vet Med Assoc 182: pp. 137-141
  13. Jacobs, A (1987) Treatment for the myelodysplastic syndromes. Hematologica 72: pp. 477-480
  14. Kaushansky, K, Seligsohn, U, Lichtman, M, Kipps, T, Prchal, J (2010) Acute myelogenous leukemia. Williams Hematology. McGraw-Hill, New York, NY, pp. 1277-1330
  15. Pui, CH, Evans, WE (1998) Acute lymphoblastic leukemia. N Engl J Med 339: pp. 605-615 CrossRef
  16. Plimack, ER, Kantarjian, HM, Issa, J-P (2007) Decitabine and its role in the treatment of hematopoietic malignancies. Leukemia and Lymphoma 48: pp. 1472-1481 CrossRef
  17. Pelham, JT, Irwin, PJ, Kay, PH (2002) Genomic hypomethylation in neoplastic cells from dogs with malignant lymphoproliferative disorders. Res Vet Sci 74: pp. 101-104 CrossRef
  18. Bryan, JN, Jabbes, M, Berent, LM, Arthur, GL, Taylor, KH, Rissetto, KC, Henry, CJ, Rahmatpanah, F, Rankin, WV, Villamil, JA, Lewis, MR, Caldwell, CW (2009) Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphoma. BMC Genetics 10: pp. 73 CrossRef
  19. Modiano, JF, Breen, M, Valli, VE, Wojcieszyn, JW, Cutter, GR (2006) Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non
• 刊物主题：Veterinary Medicine; Zoology; Transgenics;
• 出版者：BioMed Central
• ISSN：1746-6148

文摘

Background The antimetabolite 6-thioguanine (6-TG) has been used to treat both human and canine lymphoid malignancies. 6-TG has been shown to be epigenetically active as a demethylating agent in a human lymphoma cell line, causing downregulation of DNA methyltransferase 1 (DNMT1) through ubiquitin-targeted degradation. Zebularine (Zeb), a similar cytidine analog, also has demethylating activity as well as oral bioavailability. The hypothesis of the present study was that 6-TG and Zeb would cause downregulation of DNMT1 and globally demethylate the genomic DNA of canine lymphoma cells. The secondary hypothesis was that these agents would cause a dose-dependent decrease in cell proliferation in canine lymphoma cells. Canine CLGL-90 malignant T cells and CLL 17- cells were incubated in modified RPMI media. They were treated with 6-TG, Zeb, or control media at biologically relevant concentrations. Results Following treatment with each agent, DNMT1 protein and global DNA methylation were significantly decreased. A dose-dependent decrease in cell survival was also observed, with apoptosis being the primary mode of cell death in the CLGL-90 cell line. Conclusions These results confirm the demethylating action of 6-TG and Zeb in canine cells which is similar to that shown in human cell lines. Confirmation of this mechanism supports the clinical application of these compounds as demethylating drugs in veterinary patients.